# Spero Therapeutics clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Spero Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Spero Therapeutics: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/spero-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 10, 2024 | NCT06727136 | A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite... | Spero Therapeutics | Phase 1 | Completed | Healthy Participants | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727136) |
| September 29, 2023 | NCT06059846 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated... | Spero Therapeutics | Phase 3 | Completed | Urinary Tract Infection, Acute Pyelonephritis | 1,690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06059846) |
| August 1, 2023 | NCT05966688 | A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05966688) |
| July 21, 2023 | NCT05955586 | A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar... | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05955586) |
| May 12, 2023 | NCT05856747 | A Study to Compare Two Bioanalytical Assays for Tebipenem | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05856747) |
| August 11, 2022 | NCT05496374 | A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of... | Spero Therapeutics | Phase 2 | Completed | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05496374) |
| April 30, 2021 | NCT04868292 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04868292) |
| April 29, 2021 | NCT04865393 | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function | Spero Therapeutics | Phase 1 | Completed | Renal Impairment | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04865393) |
| January 14, 2021 | NCT04710407 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar... | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04710407) |
| November 12, 2020 | NCT04625855 | Study of the Absorption, Metabolism, and Excretion of \[14C\]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in... | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04625855) |
| September 17, 2020 | NCT04553406 | Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC)... | Spero Therapeutics | Phase 2 | Terminated | Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04553406) |
| June 9, 2020 | NCT04421885 | Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04421885) |
| May 6, 2020 | NCT04376554 | Effect of Tebipenem on Normal Human Intestinal Microbiota | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04376554) |
| April 30, 2020 | NCT04368585 | Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)... | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04368585) |
| January 23, 2020 | NCT04238195 | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil... | Spero Therapeutics | Phase 1 | Completed | TQT Study | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04238195) |
| November 26, 2019 | NCT04178577 | Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function | Spero Therapeutics | Phase 1 | Completed | Renal Impairment | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178577) |
| January 8, 2019 | NCT03796910 | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03796910) |
| January 3, 2019 | NCT03792308 | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03792308) |
| December 28, 2018 | NCT03788967 | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to... | Spero Therapeutics | Phase 3 | Completed | Complicated Urinary Tract Infection, Acute Pyelonephritis | 1,372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03788967) |
| January 10, 2018 | NCT03395249 | Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03395249) |
| December 18, 2017 | NCT03376529 | Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03376529) |
| January 16, 2017 | NCT03022175 | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers | Spero Therapeutics | Phase 1 | Completed | Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03022175) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 2 | 2 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Renal Insufficiency | 2 |
| Kidney Diseases | 2 |
| Mycobacterium avium-intracellulare Infection | 2 |
| Lung Diseases | 1 |
| Urinary Tract Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Security system companies in the United States](https://specstream.ai/data/businesses/security-system-companies/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
